New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 06  •  04:00PM ET
3.92
Dollar change
+0.03
Percentage change
0.77
%
Index- P/E16.55 EPS (ttm)0.24 Insider Own23.89% Shs Outstand56.89M Perf Week5.09%
Market Cap223.19M Forward P/E- EPS next Y-0.86 Insider Trans0.00% Shs Float43.33M Perf Month33.33%
Enterprise Value101.11M PEG2.42 EPS next Q-0.23 Inst Own58.24% Short Float16.47% Perf Quarter56.80%
Income14.44M P/S3.19 EPS this Y126.10% Inst Trans-3.72% Short Ratio7.56 Perf Half Y180.00%
Sales70.00M P/B1.68 EPS next Y-358.19% ROA9.13% Short Interest7.14M Perf YTD83.18%
Book/sh2.33 P/C1.56 EPS next 5Y6.84% ROE11.85% 52W High3.90 0.51% Perf Year-1.63%
Cash/sh2.51 P/FCF- EPS past 3/5Y28.55% -5.22% ROIC9.65% 52W Low1.20 228.03% Perf 3Y133.33%
Dividend Est.- EV/EBITDA20.02 Sales past 3/5Y- - Gross Margin99.51% Volatility4.92% 6.21% Perf 5Y-87.11%
Dividend TTM- EV/Sales1.44 EPS Y/Y TTM116.50% Oper. Margin6.72% ATR (14)0.20 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.73 Sales Y/Y TTM- Profit Margin20.63% RSI (14)69.39 Recom1.14
Dividend Gr. 3/5Y- - Current Ratio8.73 EPS Q/Q48.50% SMA2014.67% Beta3.13 Target Price9.17
Payout- Debt/Eq0.16 Sales Q/Q- SMA5030.09% Rel Volume1.52 Prev Close3.89
Employees24 LT Debt/Eq0.13 EarningsAug 07 BMO SMA20066.75% Avg Volume944.10K Price3.92
IPOJan 30, 2020 Option/ShortYes / Yes EPS/Sales Surpr.23.23% - Trades Volume1,427,820 Change0.77%
Date Action Analyst Rating Change Price Target Change
Sep-04-25Initiated Guggenheim Buy $8
Jul-01-25Resumed Raymond James Outperform $11
Jul-31-24Initiated Raymond James Outperform $20
Jul-14-23Initiated Piper Sandler Overweight
Jun-30-23Upgrade Stifel Hold → Buy $2 → $10
Jun-28-23Upgrade H.C. Wainwright Neutral → Buy $11
Jun-27-23Upgrade Wedbush Neutral → Outperform $10
Mar-29-22Downgrade Wedbush Outperform → Neutral
Mar-22-22Downgrade H.C. Wainwright Buy → Neutral
Sep-30-21Initiated Stifel Hold $10
Sep-25-25 12:53PM
Sep-23-25 10:23AM
Sep-22-25 09:40AM
Sep-16-25 09:47AM
Sep-12-25 09:08AM
10:53AM Loading…
Sep-05-25 10:53AM
Sep-04-25 10:46AM
Aug-19-25 12:00PM
Aug-18-25 09:40AM
Aug-07-25 07:47AM
07:30AM
Jul-15-25 04:58PM
May-29-25 08:00AM
May-12-25 04:05PM
Apr-26-25 11:00AM
08:00AM Loading…
Mar-31-25 08:00AM
Mar-25-25 12:58AM
Mar-20-25 10:42AM
Mar-19-25 07:00AM
Mar-06-25 04:09PM
04:01PM
Feb-19-25 09:15AM
Jan-12-25 06:05AM
Nov-05-24 09:00AM
08:00AM
Nov-01-24 08:00AM
Oct-07-24 04:01PM
Sep-23-24 11:43AM
07:00AM
Sep-22-24 10:00AM
03:30AM Loading…
Sep-14-24 03:30AM
Aug-08-24 04:05PM
12:00PM
Aug-06-24 01:53PM
07:37AM
07:30AM
Jun-29-24 08:28PM
06:30PM
Jun-01-24 10:00AM
May-29-24 08:00AM
May-16-24 08:23AM
May-10-24 08:46AM
May-09-24 01:54PM
07:30AM
07:28AM
Apr-29-24 08:50AM
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH GROWTH N V10% OwnerMar 19 '25Sale2.075,784,29211,997,7492,733,547Mar 20 09:01 PM